Xilio Therapeutics, Inc. Stock Price, News & Analysis

Xilio Therapeutics has appointed Tomas J. Heyman to its board of directors, enhancing the team with nearly 40 years of biopharmaceutical leadership experience. Heyman previously worked at Johnson & Johnson, overseeing substantial investments in over 120 companies. Additionally, John Maraganore, former CEO of Alnylam Pharmaceuticals, joins as a strategic advisor. These appointments aim to advance Xilio's tumor-selective immunotherapy programs, leveraging their expertise to drive value creation and innovation in cancer treatment.

Xilio Therapeutics, a biotechnology company focused on immuno-oncology therapies, will participate in a virtual fireside chat at the Morgan Stanley 20th Annual Global Healthcare Conference on September 13, 2022, at 2:55 p.m. ET. The event will be accessible via a live webcast on the company’s website, with a replay available for 30 days post-event. Xilio is advancing its proprietary GPS platform to engineer tumor-selective cytokines and checkpoint inhibitors, including clinical-stage programs XTX101 and XTX202.

Xilio Therapeutics (Nasdaq: XLO) provided an update on its clinical trials and financials on August 9, 2022. XTX101, a tumor-selective anti-CTLA-4, has exceeded its target dose in a Phase 1 trial, with plans for a Phase 2 trial in MSS colorectal cancer. The company reported a cash position of $159.4 million as of June 30, 2022, expected to sustain operations into the first half of 2024. The second quarter net loss increased to $24.6 million, reflecting a rise in general and administrative expenses. Upcoming milestones include critical data releases for XTX101 and XTX202 in 2023.

Xilio Therapeutics, Inc. (Nasdaq: XLO) announced key leadership changes on June 16, 2022. Martin Huber, M.D., is promoted to president while continuing as head of R&D. Paul Clancy is elected chair of the board, succeeding Dan Lynch, who will serve as a strategic advisor. Clancy has been part of the board since July 2020 and brings extensive financial management experience. Additionally, Robert Ross, M.D., joins the board, enhancing Xilio’s oncology expertise. These leadership changes aim to improve Xilio’s strategic direction and advance its tumor-selective immuno-oncology programs.

Xilio Therapeutics, a biotechnology company focused on tumor-selective immuno-oncology therapies, announced that Dr. Marty Huber will present at the H.C. Wainwright Global Investment Conference on May 25, 2022, at 2:30 p.m. ET. A live webcast will be available on the company’s website, with a replay accessible for 30 days. Xilio is advancing its proprietary GPS platform to create targeted therapies like XTX101, a tumor-selective anti-CTLA-4 monoclonal antibody, and XTX202, a tumor-selective IL-2, aiming to enhance anti-tumor activity while minimizing systemic effects.

Xilio Therapeutics, Inc. (Nasdaq: XLO) has appointed Stacey Davis as its new chief business officer to enhance corporate and business development strategies for future growth. With over 25 years in the life sciences sector, Davis comes from Novartis Oncology and has a proven track record in oncology and immunology. Xilio is advancing its pipeline of tumor-selective immunotherapies, with clinical data readouts expected later this year. The company aims to improve cancer treatment outcomes through its innovative geographically precise solutions (GPS) platform.

Xilio Therapeutics (Nasdaq: XLO) announced pipeline and financial highlights for Q1 2022, showcasing ongoing clinical trials for XTX202 and XTX101, with preliminary data expected later in 2022.

The company maintains a strong financial position with $177 million in cash, expected to fund operations into H1 2024. R&D expenses rose to $14.9 million, while net loss was $21.4 million for the quarter. Future prospects include submitting an IND for XTX301, a tumor-selective IL-12, later this year.

Xilio Therapeutics, Inc. (Nasdaq: XLO), a biotechnology firm focused on tumor-selective immuno-oncology therapies, will be presenting at the 21^st Annual Needham Virtual Healthcare Conference on April 14, 2022, at 8:00 a.m. ET. Dr. Marty Huber, president of research and development and chief medical officer, will lead the presentation. A live webcast will be accessible on the company’s website, with an archived replay available for 30 days.

The company utilizes its proprietary GPS platform to innovate cytokines and biologics aimed at localized anti-tumor activity.

Xilio Therapeutics, Inc. (Nasdaq: XLO) reported significant progress in its clinical pipeline and financial results for 2021. The company has $198.1 million in cash, ensuring operational continuity into 2024. Key developments include anticipated initial Phase 1 data readouts for XTX101 and XTX202 in 2022, along with plans to submit an IND for XTX301. Research and Development (R&D) expenses rose to $51.2 million for 2021, primarily due to increased personnel costs. Xilio ended the year with a net loss of $75.8 million.